Skip to content
World City Press – Lifestyle
Author:
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
October 2, 2026
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
October 1, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2026
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
September 24, 2026
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
September 23, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 21, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 9, 2026
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
August 13, 2026
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
August 5, 2026
1
2
3
Next Page
→